Gina Tomaine

News

Brentuximab Vedotin Plus AVD Demonstrates Efficacy, Safety in Hodgkin Lymphoma: BREACH Trial

08/17/2022

For patients with early stage unfavorable Hodgkin lymphoma, brentuximab vedotin combined with AVD was associated with an improved rate of PET negativity vs standard ABVD in a phase 2 trial.

For patients with early stage...

08/17/2022

Oncology

News

Odronextamab Demonstrates Promising Safety, Response in R/R Non-Hodgkin Lymphoma

11/17/2022

Gina Tomaine ;

CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.

CD20-CD3 bispecific antibody...

11/17/2022

Oncology

News

FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD

08/25/2022

Gina Tomaine ;

The FDA granted expedited approval to ibrutinib for pediatric patients with chronic GVHD after failure of 1 or more lines of systemic therapy.

The FDA granted expedited...

08/25/2022

Oncology

News

Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction

07/10/2023

Gina Tomaine ;

Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.

Switching from reference...

07/10/2023

Oncology

News

FDA Approves Brentuximab Vedotin Plus Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma

11/17/2022

Gina Tomaine ;

The FDA granted approval to brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin...

The FDA granted approval to...

11/17/2022

Oncology

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine ;

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

News

First-Line Brentuximab Vedotin Lowers Risk of Death in Classical Hodgkin Lymphoma: ECHELON-1

08/17/2022

Gina Tomaine ;

For patients with classical Hodgkin lymphoma, first-line treatment with brentuximab vedotin plus AVD resulted in a significantly lower risk of death by 41% vs standard ABVD at 6 years, according to results from the ECHELON-1 trial.

For patients with classical...

08/17/2022

Oncology

News

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

01/20/2023

Gina Tomaine ;

On January 19, 2023, the FDA approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.

On January 19, 2023, the FDA...

01/20/2023

Oncology

News

Bendamustine Demonstrates Safety, Efficacy for Lymphodepletion Before Tisagenlecleucel in R/R Large B-Cell Lymphoma

09/30/2022

Gina Tomaine ;

Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with refractory/relapsed large B-cell lymphomas, according to a recent study.

Bendamustine is an effective...

09/30/2022

Oncology

News

Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC

07/10/2023

Gina Tomaine ;

In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.

In a phase 3 study, biosimilar...

07/10/2023

Oncology